GB9720033D0 - Hepatitis B virus polypeptides - Google Patents

Hepatitis B virus polypeptides

Info

Publication number
GB9720033D0
GB9720033D0 GBGB9720033.1A GB9720033A GB9720033D0 GB 9720033 D0 GB9720033 D0 GB 9720033D0 GB 9720033 A GB9720033 A GB 9720033A GB 9720033 D0 GB9720033 D0 GB 9720033D0
Authority
GB
United Kingdom
Prior art keywords
hepatitis
fragment
virus polypeptides
hbv
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9720033.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDEVA PLC
Original Assignee
MEDEVA PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDEVA PLC filed Critical MEDEVA PLC
Priority to GBGB9720033.1A priority Critical patent/GB9720033D0/en
Publication of GB9720033D0 publication Critical patent/GB9720033D0/en
Priority to CA002304255A priority patent/CA2304255C/en
Priority to AT98944071T priority patent/ATE241013T1/de
Priority to PCT/GB1998/002852 priority patent/WO1999015671A1/en
Priority to ES98944071T priority patent/ES2199460T3/es
Priority to KR1020007002945A priority patent/KR100637282B1/ko
Priority to AU91744/98A priority patent/AU751646B2/en
Priority to EP98944071A priority patent/EP1015593B1/en
Priority to DE69814884T priority patent/DE69814884T2/de
Priority to CZ20000978A priority patent/CZ297131B6/cs
Priority to HU0003511A priority patent/HUP0003511A3/hu
Priority to PL98339366A priority patent/PL195242B1/pl
Priority to JP2000512962A priority patent/JP2001517447A/ja
Priority to NO20001397A priority patent/NO20001397L/no
Priority to US10/892,018 priority patent/US20040258709A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB9720033.1A 1997-09-19 1997-09-19 Hepatitis B virus polypeptides Ceased GB9720033D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB9720033.1A GB9720033D0 (en) 1997-09-19 1997-09-19 Hepatitis B virus polypeptides
JP2000512962A JP2001517447A (ja) 1997-09-19 1998-09-21 Ｂ型肝炎ウイルスポリペプチド
AU91744/98A AU751646B2 (en) 1997-09-19 1998-09-21 Hepatitis B virus polypeptides
DE69814884T DE69814884T2 (de) 1997-09-19 1998-09-21 Hepatitis b virale polypeptide
PCT/GB1998/002852 WO1999015671A1 (en) 1997-09-19 1998-09-21 Hepatitis b virus polypeptides
ES98944071T ES2199460T3 (es) 1997-09-19 1998-09-21 Polipeptidos del virus de la hepatitis b.
KR1020007002945A KR100637282B1 (ko) 1997-09-19 1998-09-21 Ｂ형 간염 바이러스 폴리펩티드
CA002304255A CA2304255C (en) 1997-09-19 1998-09-21 Hepatitis b virus polypeptides
EP98944071A EP1015593B1 (en) 1997-09-19 1998-09-21 Hepatitis b virus polypeptides
AT98944071T ATE241013T1 (de) 1997-09-19 1998-09-21 Hepatitis b virale polypeptide
CZ20000978A CZ297131B6 (cs) 1997-09-19 1998-09-21 Polypeptid, polynukleotid jej kódující, vektor s obsahem tohoto polynukleotidu, hostitelská bunka avakcínový prípravek
HU0003511A HUP0003511A3 (en) 1997-09-19 1998-09-21 Hepatitis b virus polypeptides
PL98339366A PL195242B1 (pl) 1997-09-19 1998-09-21 Polipeptyd, polinukleotyd, wektor, komórka gospodarza, kompozycja obejmująca polipeptyd, kompozycjaobejmująca polinukleotyd, kompozycja obejmująca wektor, zastosowanie polipeptydu, zastosowanie polinukleotydu i zastosowanie wektora
NO20001397A NO20001397L (no) 1997-09-19 2000-03-17 Hepatitt B-virus-polypeptider
US10/892,018 US20040258709A1 (en) 1997-09-19 2004-07-15 Hepatitis B virus polypeptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9720033.1A GB9720033D0 (en) 1997-09-19 1997-09-19 Hepatitis B virus polypeptides

Publications (1)

Publication Number Publication Date
GB9720033D0 true GB9720033D0 (en) 1997-11-19

Family

ID=10819394

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9720033.1A Ceased GB9720033D0 (en) 1997-09-19 1997-09-19 Hepatitis B virus polypeptides

Country Status (15)

Country Link
US (1) US20040258709A1 (enExample)
EP (1) EP1015593B1 (enExample)
JP (1) JP2001517447A (enExample)
KR (1) KR100637282B1 (enExample)
AT (1) ATE241013T1 (enExample)
AU (1) AU751646B2 (enExample)
CA (1) CA2304255C (enExample)
CZ (1) CZ297131B6 (enExample)
DE (1) DE69814884T2 (enExample)
ES (1) ES2199460T3 (enExample)
GB (1) GB9720033D0 (enExample)
HU (1) HUP0003511A3 (enExample)
NO (1) NO20001397L (enExample)
PL (1) PL195242B1 (enExample)
WO (1) WO1999015671A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009470D0 (en) 2000-04-17 2000-06-07 Univ Southampton Materials and methods relating to immune responses to fusion proteins
EP1281761A1 (en) * 2001-07-27 2003-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof.
ATE414535T1 (de) 2003-06-23 2008-12-15 Baxter Int Trägerproteine für impfstoffe
CN100537762C (zh) * 2004-06-24 2009-09-09 中国人民解放军军事医学科学院野战输血研究所 一种嵌合型病毒样颗粒疫苗载体蛋白及其制备方法与应用
EP2917231B1 (en) 2012-11-12 2019-03-06 Ruprecht-Karls-Universität Heidelberg Lipopeptides for use in treating liver diseases and cardiovascular diseases
WO2024263918A2 (en) * 2023-06-23 2024-12-26 Brii Biosciences, Inc. Assessment and treatment of chronic hepatitis b

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207535T1 (de) * 1987-06-22 2001-11-15 Medeva Holdings Bv Hepatitis-b-oberflächenantigen enthaltendes peptid
EP0389983A3 (en) * 1989-03-31 1991-01-16 Abbott Laboratories Monoclonal antibodies to pres2 and pres1 polypeptides of the hepatitis b viral envelope
AU4659993A (en) * 1992-07-07 1994-01-31 Merck & Co., Inc. Vaccine comprising mixed pres1+pres2+s and core particle
KR950702635A (ko) * 1992-07-31 1995-07-29 크리스틴 헬렌 수덴 감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria)
WO1995004151A2 (en) * 1993-07-30 1995-02-09 Medeva Holdings B.V. Vaccine compositions containing recombinant tetc-fusion proteins
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines

Also Published As

Publication number Publication date
NO20001397L (no) 2000-05-05
US20040258709A1 (en) 2004-12-23
PL195242B1 (pl) 2007-08-31
PL339366A1 (en) 2000-12-18
CA2304255A1 (en) 1999-04-01
CZ297131B6 (cs) 2006-09-13
AU751646B2 (en) 2002-08-22
EP1015593B1 (en) 2003-05-21
DE69814884T2 (de) 2004-03-11
ES2199460T3 (es) 2004-02-16
CA2304255C (en) 2009-07-07
CZ2000978A3 (cs) 2001-01-17
DE69814884D1 (de) 2003-06-26
HUP0003511A3 (en) 2003-08-28
AU9174498A (en) 1999-04-12
WO1999015671A1 (en) 1999-04-01
NO20001397D0 (no) 2000-03-17
HUP0003511A2 (hu) 2001-02-28
EP1015593A1 (en) 2000-07-05
JP2001517447A (ja) 2001-10-09
ATE241013T1 (de) 2003-06-15
KR20010024176A (ko) 2001-03-26
KR100637282B1 (ko) 2006-10-24

Similar Documents

Publication Publication Date Title
EP0608261A4 (en) COMPOSITION OF AN IMMUNREACTIVE HEPATITIS C VIRUS POLYPEPTIDE.
EP0992581A3 (en) Immunodominant human T-cell epitopes of hepatitis C virus
EP0677114A4 (en) RECOMBINED PIGROCK VIRUS.
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
PL339009A1 (en) Vaccine
EP0759935A4 (en) RECOMBINANT PAPILLOMAVIRUS L1
GR3017804T3 (en) Hepatitis b vaccine.
NZ518999A (en) Vaccine compositions
MX9603182A (es) Vacuna de hepatitis b.
MXPA03006971A (es) Tratamiento del virus de hepatitis b.
GB9720033D0 (en) Hepatitis B virus polypeptides
HU9300009D0 (en) Glycoprotein vaccine named ehv-4
EP0747482A3 (en) Recombinant hepatitis GB virus proteins their uses
TR199501557A2 (tr) PreS2 peptid iceren hepatiti b viral yüzey antijenini aritma prosesi.
EP1326895B8 (fr) Anticorps monoclonaux diriges contre des virus de l'hepatite b
GB9818133D0 (en) Vaccine
DE122007000003I1 (de) Gegen mumps Impfstoff, der ein Virus des Jeryl-Lynn Stammes enthält
WO2001093804A3 (en) Hepatitis c virus conjugates
EP0542753A4 (en) Epitopes of the pre-s region of hepatitis b virus surface antigen
EP0637631A3 (de) Hoch effiziente Expression eines Polypeptids, das eine modifizierte preS1-Region des grossen Hepatitis B-Virus-Antigens enthält.
GR3036125T3 (en) Recombinant proteins having the immunoreactivity of Hepatitis B virus e antigens (HBeAg), method for their production and their application in immunoassays and as vaccines.
AU4394101A (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)